Xeris Pharmaceuticals, Inc. (XERS) Social Stream



Xeris Pharmaceuticals, Inc. (XERS): $2.21

0.50 (+29.24%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Xeris Biopharma Holdings Inc (XERS) Price Targets From Analysts

Use the tables below to see what analysts covering Xeris Biopharma Holdings Inc think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-10-29 4 $11 $4 $7.75 $2.56 202.73%
2021-11-11 4 $11 $4.25 $7.312 $2.56 185.63%
2021-12-14 5 $11 $4.25 $6.85 $2.56 167.58%
2021-12-31 5 $11 $5.4 $7.08 $2.56 176.56%
2022-01-10 5 $11 $5.4 $7.48 $2.56 192.19%
2022-02-01 5 $11 $6 $7.6 $2.56 196.87%
2022-03-23 5 $11 $6 $7.2 $2.56 181.25%

The Trend in the Analyst Price Target


XERS's average price target has moved down $2.8 over the prior 37 weeks.

XERS reports an average of 200.05% for its upside potential over the past 48 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-06-14 4 11 9.00 9.67 3.93 146.06%
2021-11-17 5 11 4.25 6.85 2.45 179.59%
2022-01-10 5 11 5.40 7.48 2.44 206.56%
2022-02-15 5 11 6.00 7.20 2.57 180.16%
2022-03-08 5 11 6.00 7.20 2.37 203.8%

XERS Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.2 4 1 0 0 0 5

The Trend in the Broker Recommendations


Over the past 28 days, XERS's average broker recommendation rating improved by 0.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • To contextualize these metrics, consider that out of all US stocks, Xeris Biopharma Holdings Inc's average analyst price target is greater than 50.47% of them.
  • In the context of all US stocks, Xeris Biopharma Holdings Inc's variance in analysts' estimates is lower than -685.89% of them.
  • In terms of how Xeris Biopharma Holdings Inc fares relative to Healthcare stocks, note that its number of analysts covering the stock is higher than 289.38% of that group.
  • To contextualize these metrics, consider that out of stocks in the small market cap category, Xeris Biopharma Holdings Inc's upside potential (average analyst target price relative to current price) is higher than 609.49% of them.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Xeris Biopharma Holdings Inc are XENE, XBIT, and WVE.

Make investment decisions regarding XERS using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.8617 seconds.